微东颗粒通过多目标肠脑轴调节来改善功能性消化不良
Chang-Chuan Bai1, Jing-Yuan Zhang2, Jing-Ru Shen3
1Dalian Hospital of Traditional Chinese Medicine, Dalian 116000, Liaoning, China; The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Liaoning 110034, China.
概括
微唐颗粒 (WDGs) 通过调节肠道微生物群和肠-大脑轴,改善胃机动性,减少炎症和促进粘膜修复,有效治疗功能性消化不良 (FD). 这项研究阐明了WDG对FD的治疗机制.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 微生物组研究 微生物组研究
背景情况:
- 功能性消化不良 (FD) 是一种常见的胃肠道疾病,其原因复杂,治疗选择有限.
- 微唐颗粒 (WDGs) 在临床上对FD有效,但其机制尚未完全理解.
研究的目的:
- 在功能性消化不良的老鼠模型上研究WDGs的治疗效果.
- 阐明在FD中WDG治疗背后的分子机制.
主要方法:
- 建立了一种FD大鼠模型,并用WDGs治疗,评估胃机动性,激素和炎症.
- 使用UPLC-MS进行WDG化学分析,胃组织的转录组学和肠道微生物群分析.
- 综合多学科数据和使用组织学和分子技术验证的机制.
主要成果:
- WDGs显著改善了FD症状,增强了胃排空,并减少了胃损伤.
- WDGs调节了肠道微生物群,增加了短链脂肪酸 (SCFA) 产量,并激活了肠-大脑轴.
- WDGs调节了胃肠道激素,减少了炎症,并促进了胃粘膜的修复.
结论:
- WDG通过编排肠道微生物群-SCFA-肠道-大脑轴信号来治疗FD.
- WDGs增强胃的运动性,减少炎症和氧化应激,并促进粘膜的修复.
- 这项研究为FD治疗中WDGs的临床使用提供了科学基础.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
625
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
625
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
880
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
880
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K
Hormonal Regulation
47.7K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
47.7K
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
564
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
564


